T

Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867

Watchlist Manager
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
Watchlist
Price: 8.15 CNY -0.49%
Market Cap: 15.9B CNY
Have any thoughts about
Tonghua Dongbao Pharmaceutical Co Ltd?
Write Note

Tonghua Dongbao Pharmaceutical Co Ltd
Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tonghua Dongbao Pharmaceutical Co Ltd
Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash CAGR 3Y CAGR 5Y CAGR 10Y
T
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
Cash
ÂĄ477.4m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash
ÂĄ22.4B
CAGR 3-Years
74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash
ÂĄ8.8B
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash
ÂĄ22.3B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash
ÂĄ14.1B
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash
ÂĄ391.7m
CAGR 3-Years
1 693%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tonghua Dongbao Pharmaceutical Co Ltd
Glance View

Market Cap
16.2B CNY
Industry
Pharmaceuticals

Nestled in the bustling heart of China's pharmaceutical industry, Tonghua Dongbao Pharmaceutical Co., Ltd. has carved out a distinctive niche in the world of diabetes care. Since its inception, the company has been focused on developing, manufacturing, and distributing a range of innovative pharmaceutical products, primarily concentrating on insulin products. With its headquarters strategically located in Tonghua City—a region known for its rich medicinal resources—the company integrates advanced biotechnological processes with traditional pharmaceutical practices. Tonghua Dongbao’s competitive edge lies in its ability to harness cutting-edge technology to produce high-quality insulin products efficiently, allowing it to tap into the rapidly growing domestic and international markets. As diabetes continues to be a major global health challenge, this focus on insulin has positioned the company as a critical player in the fight to manage and treat this chronic disease. Their revenue model is underscored by a keen focus on the production of insulin and its analogs, which represent a significant portion of its sales. Beyond insulin, Tonghua Dongbao also produces a range of other pharmaceuticals, contributing to a diversified product portfolio that supports steady revenue streams. Importantly, the company’s investment in R&D has led to a robust pipeline of new and improved therapeutics aimed at expanding their reach and maintaining competitive advantage. Through strategic partnerships and collaborations, both within China and internationally, Tonghua Dongbao continues to amplify its market presence. In doing so, it exemplifies a commitment not only to financial growth but also to advancing healthcare outcomes for millions of diabetes patients around the globe.

Intrinsic Value
10.09 CNY
Undervaluation 19%
Intrinsic Value
Price
T

See Also

What is Tonghua Dongbao Pharmaceutical Co Ltd's Cash?
Cash
477.4m CNY

Based on the financial report for Sep 30, 2024, Tonghua Dongbao Pharmaceutical Co Ltd's Cash amounts to 477.4m CNY.

What is Tonghua Dongbao Pharmaceutical Co Ltd's Cash growth rate?
Cash CAGR 3Y
-2%

Over the last year, the Cash growth was -28%. The average annual Cash growth rates for Tonghua Dongbao Pharmaceutical Co Ltd have been -2% over the past three years .

Back to Top